![“We're gonna free the data,” Sharpless pledges at NCI Town Hall](https://cdn.cancerletter.com/media/2017/12/slideshow2-web.jpg)
![“We're gonna free the data,” Sharpless pledges at NCI Town Hall](https://cdn.cancerletter.com/media/2017/12/slideshow2-web.jpg)
Cover Story
By Matthew Bin Han Ong
In his first talk to NCI staff, director Norman “Ned” Sharpless presented himself as an institute insider—highlighting his career-long relationships with NCI and its “legends,” demonstrating his grasp of the institute's agenda and research portfolio.
In Brief
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
Drugs & Targets
Trending Stories
- FDA grants Cytotron Breakthrough Device Designation for breast, liver and pancreatic cancers
- Tracking Trump’s early impact on cancer policy
Research and care disrupted, NCI programs face unpredictable future - Foundations acquire a critical new role as federal funding for cancer research falters
- Beyond the $500B Stargate Project: The frontier of AI in oncology beckons
- Our challenge: To find zen in chaos
- What Trump’s pick of RFK Jr. means for cancer: Epidemics, HPV, stunted research
Former FDA Commissioner Scott Gottlieb expresses “deep concerns”